Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

The stability of treprostinil sodium after dilution in three common i.v. infusion vehicles was assessed. The chemical stability of treprostinil sodium was tested over a 48-hour period at 40 °C ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...

At the moment, the only FDA-approved treatment for PH-ILD is United Therapeutics' Tyvaso inhaled prostacyclin analogue (treprostinil), which is delivered either using a nebuliser or as a DPI four ...

Commercially available solutions of treprostinil sodium a, b were diluted in sterile water for injection, c 0.9% sodium chloride injection, d and 5% dextrose injection. e The concentrations tested ...